Jefferies Defends Epizyme (EPZM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Why BofA says July Fed rate hike would be "unprecedented"
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
FDA AdCom Positive on Epizyme (EPZM) Tazemetostat
December 18, 2019 11:48 AM ESTFDA AdCom positive on Epizyme (NASDAQ: EPZM) Tazemetostat. 11 Yes votes that the benefits outweigh the risks. 0 No votes. (shares halted)
... MorePre-Open Movers 12/16: (AXSM) (INFN) (BMRN) Higher (WVE) (PCG) (BA) Lower (more...)
December 16, 2019 9:23 AM ESTToday's Pre-Open Movers
Axsome Therapeutics, Inc. (NASDAQ: AXSM) 78.5% HIGHER; announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary endpoint and rapidly and significantly improved symptoms of depression in the GEMINI Phase 3 trial in major depressive disorder (MDD). The GEMINI study was a randomized, double-blind, placebo-controlled, multi-center, U.S. trial, in which 327 adult patients with confirmed moderate to severe MDD were randomized to treatment with either AXS-05 (dextromethorphan/bupropion modulated delivery tablet) or placebo once daily for the first 3 days and twice... More
Epizyme (EPZM) on watch with FDA briefing documents released
December 16, 2019 8:24 AM ESTEpizyme (NASDAQ: EPZM) on watch with FDA briefing documents released (LINK)
... More